No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comNo one on the platform currently holds 0IV3.L.
No tracked institution reports a position in 0IV3.L as of their last filing.
No one on the platform has traded 0IV3.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 138.8% | 273.5% | ||||
| Profit Margin % | -45.4% | -22021.4% | -16053.2% | |||
| Free Cash Flow Margin % | -60.4% | -19958.5% | -14011.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $236M | +26.8% | $-0.04 | $-0.05–$-0.04 | — | 1 |
| 2027 | $342M | +44.7% | $0.07 | $0.07–$0.09 | — | 1 |
| 2028 | $526M | +53.9% | $0.25 | $0.24–$0.29 | — | 1 |
| 2029 | $705M | +33.9% | $0.45 | $0.42–$0.52 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.01 | $-0.02 | -125.2% |
| 2026-05-06 | $-0.02 | $-0.01 | +50.0% |
| 2026-02-25 | $-0.03 | $-0.05 | -66.7% |
| 2025-11-05 | $-0.03 | $-0.03 | +13.1% |
| 2025-08-06 | $-0.03 | $-0.02 | +15.6% |
| 2025-05-07 | $-0.04 | $-0.03 | +17.0% |
| 2025-02-26 | $-0.02 | $-0.04 | -55.1% |
| 2024-11-07 | $-0.08 |
| $-0.04 |
| +52.3% |
| $367M |
| — |
| 0IIM.LEsperion Therapeutics, Inc. | $3.19 | +0.14% | $707M | — |
| 0JDK.LIovance Biotherapeutics, Inc. | $10.32 | +5.85% | $3.9B | — |
Source: Financial Modeling Prep · peers by sector/industry